Loading...

PODCAST

Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

science life sciences

All Episodes

1:47

Pharmaceutical Executive Daily: Leadership Turnover...

Pharmaceutical Executive ·

2026/04/02

In today’s Pharmaceutical Executive Daily, leadership turnover continues across key federal health agencies under the Trump administration, Shionogi enters a $2 billion agreement to acquire rights to Radicava, and the FTC examines antitrust concerns tied to CVS Health’s integrated healthcare model.

en-us

2:53

Pharmaceutical Executive Daily: Trump Administration...

Pharmaceutical Executive ·

2026/04/01

In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK Jr.'s vaccine policy overhaul as political pressures mount ahead of the midterm elections, Biogen agrees to acquire Apellis Pharmaceuticals in a deal valued at approximately $5.6 billion, and Pharmaceutical Executive examines the risk-reward calculus facing R&D leaders in today's volatile development environment.

en-us

2:28

Pharmaceutical Executive Daily: Novo Nordisk's Wegovy...

Pharmaceutical Executive ·

2026/03/31

In today's Pharmaceutical Executive Daily, Novo Nordisk launches the first multi-month subscription program for Wegovy targeting cash-paying patients through telehealth partners, Merck enters an $838 million research collaboration with antibody discovery startup Infinimmune, and Eli Lilly agrees to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion to expand into sleep-wake disorder treatments.

en-us

2:49

Pharmaceutical Executive Daily: Eli Lilly Presses...

Pharmaceutical Executive ·

2026/03/30

In today's Pharmaceutical Executive Daily, Eli Lilly presses the U.K. government to overhaul its NHS drug pricing framework as a condition of resuming investment in the country, Lilly also announces a deal worth up to $2.75 billion with AI drug discovery company Insilico Medicine to accelerate development of novel therapeutics across multiple disease areas, and Pharmaceutical Executive speaks with the co-founder and CEO of Soley Therapeutics about the company's biology-first approach to drug

en-us

3:17

Pharmaceutical Executive Daily: Novartis Acquires...

Pharmaceutical Executive ·

2026/03/27

In today's Pharmaceutical Executive Daily, Novartis agrees to acquire Excellergy for up to $2 billion to advance a next-generation anti-IgE therapy while Otsuka moves to acquire Transcend Therapeutics in a deal valued at up to $1.225 billion, the FDA approves two first-of-their-kind therapies in Novo Nordisk's once-weekly basal insulin Awiqli and Rocket Pharmaceuticals' gene therapy Kresladi for a rare pediatric immune disease, and a new commentary argues that orphan drug manufacturers should be

en-us

2:42

Pharmaceutical Executive Daily: Trump Administration...

Pharmaceutical Executive ·

2026/03/26

In today's Pharmaceutical Executive Daily, the Trump administration misses a statutory deadline to nominate a permanent CDC director, leaving the agency in continued leadership limbo, the FDA grants accelerated approval to Denali Therapeutics' Avlayah as the first therapy designed to cross the blood-brain barrier and treat the neurological manifestations of Hunter syndrome, and a new Pharmaceutical Executive commentary breaks down what CMS's updated ASP reporting requirements mean for Part B drug

en-us

2:57

Pharmaceutical Executive Daily: FDA Issues Warning...

Pharmaceutical Executive ·

2026/03/25

In today's Pharmaceutical Executive Daily, the FDA issues a warning letter to ImmunityBio over misleading promotional claims about its bladder cancer therapy Anktiva, Merck agrees to acquire Terns Pharmaceuticals in a $6.7 billion deal while Shionogi moves to take full ownership of the Shionogi-Apnimed Sleep Science joint venture, and a new commentary examines the structural pricing problem sitting at the center of the GLP-1 access debate.

en-us

2:29

Pharmaceutical Executive Daily: Bayer Shares Drop...

Pharmaceutical Executive ·

2026/03/24

In today's Pharmaceutical Executive Daily, Bayer shares briefly dip after activist investor Inclusive Capital offloads its remaining stake at a loss, Quotient Therapeutics enters a multi-year research collaboration with Merck to discover novel drug targets in inflammatory bowel disease, and Gilead Sciences agrees to acquire privately held Ouro Medicines in a deal valued at up to $2.18 billion.

en-us

2:41

Pharmaceutical Executive Daily: Pfizer Warns...

Pharmaceutical Executive ·

2026/03/23

In today's Pharmaceutical Executive Daily, Pfizer warns shareholders to reject an unsolicited mini-tender offer from Tutanota LLC seeking to purchase up to one million shares at a potentially below-market price, the FDA grants expanded approval to Rhythm Pharmaceuticals' Imcivree as the first approved treatment for acquired hypothalamic obesity, and a new commentary makes the case that AI-powered roleplay data is an untapped source of commercial intelligence for pharma field teams.

en-us

2:56

Pharmaceutical Executive Daily: FDA Approves Wegovy HD

Pharmaceutical Executive ·

2026/03/20

In today's Pharmaceutical Executive Daily, Novartis agrees to acquire a pan-mutant-selective inhibitor from Synnovation Therapeutics in a deal worth up to $3 billion while Collegium moves to acquire Azstarys from Corium Therapeutics, the FDA grants accelerated approval to Wegovy HD, a higher-dose version of Novo Nordisk's semaglutide injection, supported by Phase III data showing roughly 21% mean weight loss, and an analysis on agentic AI and what it means for commercial operations in life

en-us

10:17

The Ron Lanton Report: When Policy Becomes a Capital...

Pharmaceutical Executive ·

2026/03/20

The episode explores how regulatory signals across drug approvals, trade policy, AI governance, and drug pricing shape business strategy and investor decisions before formal rules are ever finalized.

en-us

2:33

Pharmaceutical Executive Daily: Analysis on TrumpRx...

Pharmaceutical Executive ·

2026/03/19

In today's Pharmaceutical Executive Daily, a new analysis finds that TrumpRx is listing prices for roughly a third of its featured drugs higher than what patients in the United Kingdom pay, two biotech companies focused on next-generation T-cell engager therapies close significant funding rounds, and Pharmaceutical Executive sits down with Jeanne Marrazzo of the Infectious Diseases Society of America on the worsening U.S. measles outbreak and what it means for the future of vaccine confidence.

en-us

2:36

Pharmaceutical Executive Daily: Federal Judge Halts...

Pharmaceutical Executive ·

2026/03/18

In today's Pharmaceutical Executive Daily, a federal judge blocks RFK Jr.'s reconstituted vaccine advisory committee and halts its policy changes, a new analysis breaks down what recent Gartner predictions on AI mean for healthcare marketers, and the FDA approves Icotyde as the first oral targeted therapy for moderate-to-severe plaque psoriasis.

en-us

2:08

Pharmaceutical Executive Daily: Conflict in Middle...

Pharmaceutical Executive ·

2026/03/16

In today's Pharmaceutical Executive Daily, ongoing conflict in the Middle East is straining pharmaceutical supply routes to the Gulf region, Sentynl Therapeutics enters a licensing agreement with PRG-ST to advance a progerin-targeting therapy for progeria, and a new analysis examines the innovations, integration challenges, and early hurdles shaping the emerging biotech landscape.

en-us

2:31

Pharmaceutical Executive Daily: FDA Expands Approval...

Pharmaceutical Executive ·

2026/03/13

In today's Pharmaceutical Executive Daily, a new West Health-Gallup survey finds that more than 82 million Americans have cut back on daily expenses to cover healthcare costs, the FDA expands the approved age indication for GSK's RSV vaccine Arexvy to adults aged 18 to 49 at increased risk, and a new commentary argues that agentic AI is positioned to fundamentally reshape commercial operations in life sciences.

en-us

2:35

Pharmaceutical Executive Daily: Senate Democrats...

Pharmaceutical Executive ·

2026/03/12

en-us

8:16

Moving CAR-T Beyond Oncology

Pharmaceutical Executive ·

2026/03/11

Vincent Hennemand discusses using these types of therapies to develop treatments for autoimmune conditions.

en-us

2:27

Pharmaceutical Executive Daily: FDA's New Guidance...

Pharmaceutical Executive ·

2026/03/11

In today's Pharmaceutical Executive Daily, the FDA issues new draft guidance aimed at reducing the cost and complexity of biosimilar development, Novo Nordisk responds to an FDA warning letter stemming from a 2025 inspection of its U.S. headquarters, and Pharmaceutical Executive's latest analysis examines the state of the biopharma industry as it navigates a period of cautious momentum.

en-us

2:24

Pharmaceutical Executive Daily: FDA Expands Approval...

Pharmaceutical Executive ·

2026/03/10

In today's Pharmaceutical Executive Daily, the FDA approves leucovorin as the first-ever treatment for an ultra-rare genetic condition called cerebral folate transport deficiency, Enhertu receives FDA Priority Review for HER2-positive early breast cancer in the post-neoadjuvant setting, and a new commentary argues that AI has fundamentally changed how healthcare communicators must think about content strategy.

en-us

1:50

Pharmaceutical Executive Daily: Vinay Prasad Set to...

Pharmaceutical Executive ·

2026/03/09

In today’s Pharmaceutical Executive Daily, Vinay Prasad exits the FDA’s Center for Biologics Evaluation and Research for the second time in under a year, major deal activity including a GSK and Alfasigma licensing agreement along with Servier’s $2 billion acquisition of Day One Pharmaceuticals, and Ipsen withdraws Tazverik from the market following emerging clinical trial data.

en-us

463 results

Similar Podcasts

Rabbit Hole of Research

Jotham Austin, II PhD, Nick Elizalde,...

Show Me the Science with Luke O"Neill

Newstalk

Planetterrian Daily

Patrick · Nerra Network

Sleep Science

Sleep Science

BioSpace

BioSpace